• United Therapeutics received FDA clearance to begin a Phase 1 trial of Treprostinil-Iloprost SMI in healthy volunteers.
• A Phase 2 trial in pulmonary arterial hypertension patients is expected in 2027, contingent on successful Phase 1 results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610280700BIZWIRE_USPR_____20261028_BW830210) on October 28, 2026, and is solely responsible for the information contained therein.